LeMaitre Vascular, Inc. (NASDAQ:LMAT) Plans Quarterly Dividend of $0.16

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Thursday, August 1st, Zacks reports. Investors of record on Thursday, August 15th will be given a dividend of 0.16 per share by the medical instruments supplier on Thursday, August 29th. This represents a $0.64 annualized dividend and a yield of 0.75%. The ex-dividend date is Thursday, August 15th.

LeMaitre Vascular has raised its dividend payment by an average of 13.8% annually over the last three years and has raised its dividend every year for the last 13 years. LeMaitre Vascular has a payout ratio of 32.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect LeMaitre Vascular to earn $1.97 per share next year, which means the company should continue to be able to cover its $0.64 annual dividend with an expected future payout ratio of 32.5%.

LeMaitre Vascular Stock Performance

LMAT traded down $1.24 on Friday, hitting $85.01. 348,354 shares of the company were exchanged, compared to its average volume of 157,693. The firm has a fifty day simple moving average of $82.69 and a two-hundred day simple moving average of $71.68. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $91.76. The stock has a market capitalization of $1.91 billion, a PE ratio of 56.30, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same period last year, the company earned $0.37 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, equities analysts expect that LeMaitre Vascular will post 1.77 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the transaction, the chief executive officer now owns 2,079,128 shares in the company, valued at $156,558,338.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the transaction, the chief executive officer now owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 127,437 shares of company stock worth $10,076,242. 10.79% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday. Barrington Research lifted their price target on LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday. They set a “buy” rating and a $105.00 price target on the stock. Finally, Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $83.71.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.